

August 2, 2012



# Oncolytics Biotech® Inc. Announces Second Quarter 2012 Results

CALGARY, Aug. 2, 2012 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended June 30, 2012.

"Early in the quarter, we announced that we had completed enrollment in the first, 80-patient stage of our Phase III trial in head and neck cancers," said Dr. Brad Thompson, President and CEO of Oncolytics. "We continued to make progress on this key clinical initiative during the quarter with our independent Data Monitoring Committee recommending the trial proceed based on a review of the safety data. We continue to await the results of an ongoing data review which will enable us to determine the next steps for the study."

## **Selected Highlights**

Since March 31, 2012, the Company has made a number of significant announcements:

### **Clinical Trial Program**

- Completion of enrollment in the first, 80-patient stage of its Phase III clinical trial examining REOLYSIN® in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018);
- Review by Company's independent Data Monitoring Committee (DMC) of the safety data for the first stage of the Company's Phase III trial in head and neck cancers and received a recommendation that enrollment continue in the study while awaiting the ongoing data review;
- Entry into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN in patients with advanced or metastatic colorectal cancer enrolling up to 100 patients;
- Entry into an agreement whereby the NCIC CTG will sponsor and conduct a randomized Phase II study of REOLYSIN in patients with advanced or metastatic non-small cell lung cancer enrolling up to 150 patients;
- Entry into an agreement whereby the NCIC CTG will sponsor and conduct a randomized Phase II study of REOLYSIN in patients with advanced or metastatic breast cancer enrolling up to 100 patients; and

### **Clinical Trial Results**

- Publication of a paper entitled "Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients," in the June 13, 2012 issue of the journal Science Translational Medicine (Vol. 4 Issue 138 138ra77), covering findings from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases. The researchers found that intravenously-administered reovirus could specifically target and infect metastatic liver tumors in 90% of the patients, even though all patients treated had had a pre-existing immunity to the virus.

**ONCOLYTICS BIOTECH INC.**  
**INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**  
*(unaudited)*

	June 30, 2012 \$	December 31, 2011 \$
<b>Assets</b>		
<b>Current assets</b>		
Cash and cash equivalents	33,802,813	32,918,751
Short-term investments	1,969,228	1,936,787
Accounts receivable	89,574	55,392
Prepaid expenses	699,348	721,576
<b>Total current assets</b>	<b>36,560,963</b>	<b>35,632,506</b>
<b>Non-current assets</b>		
Property and equipment	428,167	392,111
<b>Total non-current assets</b>	<b>428,167</b>	<b>392,111</b>
<b>Total assets</b>	<b>36,989,130</b>	<b>36,024,617</b>
<b>Liabilities And Shareholders' Equity</b>		
<b>Current Liabilities</b>		
Accounts payable and accrued liabilities	5,302,680	6,504,238
<b>Total current liabilities</b>	<b>5,302,680</b>	<b>6,504,238</b>
<b>Shareholders' equity</b>		
Share capital		
Authorized: unlimited		
Issued:		
June 30, 2012 - 76,606,085		
December 31, 2011 - 71,251,335	197,947,858	177,282,566
Warrants	3,030,519	2,653,627
Contributed surplus	20,821,795	21,142,519
Accumulated other comprehensive loss	(35,560)	(117,501)
Accumulated deficit	(190,078,162)	(171,440,832)
<b>Total shareholders' equity</b>	<b>31,686,450</b>	<b>29,520,379</b>
<b>Total liabilities and equity</b>	<b>36,989,130</b>	<b>36,024,617</b>

**ONCOLYTICS BIOTECH INC.**  
**INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS**  
*(unaudited)*

	<b>Three Month Period Ending June 30, 2012 \$</b>	<b>Three Month Period Ending June 30, 2011 \$</b>	<b>Six Month Period Ending June 30, 2012 \$</b>	<b>Six Month Period Ending June 30, 2011 \$</b>
<b>Expenses</b>				
Research and development	<b>9,053,329</b>	5,483,131	<b>16,543,873</b>	8,454,742
Operating	<b>1,222,090</b>	1,068,623	<b>2,310,141</b>	2,195,634
<b>Operating loss</b>	<b>(10,275,419)</b>	(6,551,754)	<b>(18,854,014)</b>	(10,650,376)
Write down of asset available for sale	—	(735,681)	—	(735,681)
Change in fair value of warrant liability	—	—	—	36,000
Interest	<b>93,389</b>	123,197	<b>213,456</b>	214,703
<b>Loss before income taxes</b>	<b>(10,182,030)</b>	(7,164,238)	<b>(18,640,558)</b>	(11,135,354)
Income tax expense	<b>3,228</b>	—	<b>3,228</b>	—
<b>Net loss</b>	<b>(10,178,802)</b>	(7,164,238)	<b>(18,637,330)</b>	(11,135,354)
Other comprehensive loss (income) - translation adjustment	<b>116,200</b>	(75,211)	<b>81,941</b>	(38,331)
<b>Net comprehensive loss</b>	<b>(10,062,602)</b>	(7,239,449)	<b>(18,555,389)</b>	(11,173,685)
<b>Basic and diluted loss per common share</b>	<b>(0.13)</b>	(0.10)	<b>(0.25)</b>	(0.16)
<b>Weighted average number of shares (basic and diluted)</b>	<b>76,542,861</b>	71,209,164	<b>75,547,842</b>	70,586,073

**ONCOLYTICS BIOTECH INC.**  
**INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS**  
*(unaudited)*

	Three Month Period Ending June 30, 2012 \$	Three Month Period Ending June 30, 2011 \$	Six Month Period Ending June 30, 2012 \$	Six Month Period Ending June 30, 2011 \$
<b>Operating Activities</b>				
Net loss for the period	(10,178,802)	(7,164,238)	(18,637,330)	(11,135,354)
Amortization - property and equipment	29,510	29,992	57,571	47,267
Share based compensation	58,343	40,469	72,196	43,342
Change in fair value of warrant liability	—	—	—	(36,000)
Write down of asset available for sale	—	735,681	—	735,681
Unrealized foreign exchange loss	61,171	28,978	16,162	220,127
Net change in non-cash working capital	(1,174,059)	1,417,496	(1,213,512)	1,357,514
<b>Cash used in operating activities</b>	<b>(11,203,837)</b>	<b>(4,911,622)</b>	<b>(19,704,913)</b>	<b>(8,767,423)</b>
<b>Investing Activities</b>				
Acquisition of property and equipment	(61,695)	(33,831)	(93,627)	(49,107)
Purchase of short-term investments	—	1,679,940	(32,441)	1,679,940
<b>Cash used in investing activities</b>	<b>(61,695)</b>	<b>1,646,109</b>	<b>(126,068)</b>	<b>1,630,833</b>
<b>Financing Activities</b>				
Proceeds from exercise of stock options and warrants	422,886	23,300	885,469	14,738,597
Proceeds from public offering	(31,648)	—	19,763,795	—
<b>Cash provided by financing activities</b>	<b>391,238</b>	<b>23,300</b>	<b>20,649,264</b>	<b>14,738,597</b>
<b>Increase in cash</b>	<b>(10,874,294)</b>	<b>(3,242,213)</b>	<b>818,283</b>	<b>7,602,007</b>
Cash and cash equivalents, beginning of period	44,622,078	49,912,873	32,918,751	39,296,682
Impact of foreign exchange on cash and cash equivalents	55,029	(30,429)	65,779	(258,458)
<b>Cash and cash equivalents, end of period</b>	<b>33,802,813</b>	<b>46,640,231</b>	<b>33,802,813</b>	<b>46,640,231</b>

**To view the Company's Second Quarter 2012 Consolidated Financial Statements, related Notes to Consolidated Financial Statements, and Management's Discussion and Analysis, please see the Company's quarterly filings which will be available on [www.sedar.com](http://www.sedar.com) and on [www.oncolyticsbiotech.com](http://www.oncolyticsbiotech.com).**

**About Oncolytics Biotech Inc.**

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: [www.oncolyticsbiotech.com](http://www.oncolyticsbiotech.com).

*This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2012 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies*

*involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.*

SOURCE Oncolytics Biotech Inc.